Welcome to the 8th Annual Translational Workshop
on Hematologic Malignancies

Please use the link below to join the live session on
FRIDAY, OCTOBER 8th AT 10 AM EASTERN / 7 AM PACIFIC

The meeting agenda is provided below, along with pre-recorded presentations for viewing.
You can also review instructions on how to use the Slack application which will be used for discussions before, during, and after the live meeting.

We gratefully acknowledge this year’s meeting sponsors: AstraZeneca, BeiGene, Bristol-Myers Squibb, Genmab, GlaxoSmithKline, and Janssen

  • Agenda
  • Pre-recorded Presentations
  • Posters

10:00-10:30 AM
30 min

 

KEYNOTE: Harmony Project – Lessons and Pitfalls
Peter Sonneveld, Erasmus University of Rotterdam, Rotterdam, The Netherlands

10:30-11:00 AM
30 min

Breakout Session: Large-scale profiling efforts
  • 1-minute Recaps: Madhav Dhodapkar, David Maloney, Bruno Paiva recap key takeaways from pre-recorded presentation in 60s each
  • Breakout group discussions and report out

11:00-11:20 AM
30 min

Immune Regulation and Targeting in Myeloma
  • 1-minute Recaps: Nikhil Munshi, Bruno Paiva, Niels van de Donk recap key takeaways from pre-recorded presentation in 60s each
  • Panel discussion with pre-recorded presenters: Eric Smith, Paola Neri, Ken Anderson

11:20-11:30 AM
10 min

Break

11:30-11:50 PM
20 min

Immune Regulation and Targeting in Leukemi

  • 1-minute Recaps: Ana Alfonso, Kieron Dunleavy, Catherine Lai recap key takeaways from pre-recorded presentation in 60s each
  • Panel discussion with pre-recorded presenters: Courtney DiNardo, Nitin Jain, Bijal Shah

11:50-12:20 PM
30 min

Breakout Session: CAR T-cell Therapies in FL, MM, CLL – Questions of persistence

  • Breakout group discussions and report out

12:20-12:30 PM
10 min

Break

12:30-12:45 PM
15 min

AstraZeneca Hematology Translational Strategy beyond Acalabrutinib

Veerendra Munugalavadla, PhD

12:45-1:05 PM
20 min

Immune Regulation and Targeting in Lymphoma

  • 1-minute Recaps: Sonali Smith, Stephen Ansell, Ciara Freeman, Adrian Wiestner recap key takeaways from
    pre-recorded presentation in 60s each
  • Panel discussion with pre-recorded presenters: Laurence de Leval, Martin Hutchings, Loretta Nastoupil, John Gribben

1:05-1:50 PM
45 min

Breakout Sessions: Lessons Learned Across Disease States

  • 1-minute Recaps: Noopur Raje, Daphne de Jong, Alfred Garfall recap key takeaways from pre-recorded presentation
    in 60s each Breakout group discussions and report out:
    • Topic 1: Cellular Therapies
    • Topic 2: Novel Targets

1:50-2:00 PM
10 min

Wrap Up and Next Steps

Presentations Videos

Large-scale profiling efforts (15-minute presentations)

Liquid Biopsy & cfDNA

Davide Rossi, MD, PhD, Oncology Institute of Southern Switzerland

TCR Clonotype Analysis/Immunoprofiling

Albert Yeh, Fred Hutchinson Cancer Research Center, Seattle, Washington

Integrated Genomic and Epigenomic Analysis of Multiple Myeloma

Benjamin Barwick, PhD, Winship Cancer Institute, Emory University, Atlanta, Georgia Recap: Bruno Paiva, PhD, University of Navarra, Pamplona, Spain

Immune Regulation and Targeting in Leukemia (15-minute presentations)

Mutational testing and treatment initiation

Courtney DiNardo, MD, UT MD Anderson Cancer Center, Houston, Texas

Targets Beyond BCL2

Nitin Jain, MD, UT MD Anderson Cancer Center, Houston, Texas

CAR T for ALL

Bijal Shah, MD, Moffitt Cancer Center, Tampa, Florida

Immune Regulation and Targeting in Lymphoma (15-minute presentations)

Updates on our Understanding of T Cell Lymphoma Pathogenesis

Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland

Bispecific Antibodies, CD20, CD3, T-cell subsets, immune profiling

Martin Hutchings, MD, PhD, Rigshospitalet, Copenhagen, Denmark

AntiCD19 CARs, ADCs, monoclonals

Loretta Nastoupil, MD, UT MD Anderson Cancer Center, Houston, Texas

Effects of BTK inhibitors on the microenvironment – What have we learned over the last 5 years?

John Gribben, MD, DSc, Barts Cancer Institute, London, United Kingdom

Immune Regulation and Targeting in Myeloma (15-minute presentations)

Mechanisms of resistance to CAR T cells in myeloma

Eric Smith, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Mechanism of IMID resistance, and strategies for overcoming

Paola Neri, MD, PhD, University of Calgary, Calgary, Alberta, Canada

Targeting myeloma in the bone marrow microenvironment

Ken Anderson, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

New Platforms and New Targets – Cross-disease discussions

Nina Shah, UCSD, San Francisco, California

Jennifer Brudno, MD, National Cancer Institute, Bethesda, Maryland

Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, Pennsylvania

Catherine Bollard, MD, Children’s National Hospital, Washington, District of Columbia

Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York, New York

Carlos Ramos, MD, Baylor College of Medicine, Houston, Texas

Larry Boise, PhD, Winship Cancer Center of Emory University, Atlanta, Georgia

Laura Pasqualucci, MD, Columbia University, New York, New York

Leukemia: Kamil Kranc, PhD, DPhil,, Barts Cancer Institute, London, United Kingdom

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio, neque qui velit. Magni dolorum quidem ipsam eligendi, totam, facilis laudantium cum accusamus ullam voluptatibus commodi numquam, error, est. Ea, consequatur.